Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Study Type
OBSERVATIONAL
Enrollment
100
Apretude for PrEP
Midway Specialty Care Center
Orlando, Florida, United States
Midway Specialty Care Center
Temple Terrace, Florida, United States
Midway Specialty Care Center
West Palm Beach, Florida, United States
Describe the percent of cisgender females persistent on CAB-LA over 44 weeks.
Time frame: 44 Weeks
Describe incidence of bacterial STIs through weeks 20, 44 and 92
Time frame: Weeks 20, 44 and 92
Describe satisfaction of cisgender female patients while being on CAB-LA through weeks 20, 44 and 92 with the use of satisfaction surveys
Time frame: Weeks 20, 44 and 92
Describe percentage adherence to CAB-LA injection schedule at weeks 20, 44 and 92 for cisgender females
Time frame: Weeks 20, 44 and 92
Describe percentage adherence to CAB-LA injection schedule at weeks 20, 44 and 92 for cisgender females with substance use and/or unstable housing.
Time frame: Weeks 20, 44 and 92
Describe percentage of cisgender female patients with HIV prevention failure while on CAB-LA, with detection of HIV, at weeks 20, 44 and 92.
Time frame: Weeks 20, 44 and 92
Describe percentage of cisgender female patients with weight gain > 10% from baseline on CAB-LA at weeks 20, 44 and 92
Time frame: Weeks 20, 44 and 92
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.